Skip Navigation


Cardiovascular Research Advance Access first published online on July 18, 2009
This version [Corrected Proof] published online on August 4, 2009
Cardiovascular Research, doi:10.1093/cvr/cvp241
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
84/3/353    most recent
cvp241v2
cvp241v1
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Apostolakis, S.
Right arrow Articles by Spandidos, D. A.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Apostolakis, S.
Right arrow Articles by Spandidos, D. A.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Published on behalf of the European Society of Cardiology. All rights reserved. © The Author 2009. For permissions please email: journals.permissions@oxfordjournals.org.

Interleukin 8 and cardiovascular disease

Stavros Apostolakis, Konstantina Vogiatzi, Virginia Amanatidou and Demetrios A. Spandidos*

Laboratory of Clinical Virology, Faculty of Medicine, University of Crete, 71409 Heraklion, Crete, Greece

* Corresponding author. Tel: +30 2810394633; fax: +30 210 725 2922. E-mail address: spandidos{at}spandidos.gr

Since the establishment of the inflammatory basis of atherosclerosis, several pro- or anti-inflammatory agents have been examined as potential mediators of the biochemical pathways of lesion formation. Interleukin (IL)-8 was first characterized in 1987. Since then, knowledge regarding its role in leucocyte trafficking and activation has advanced rapidly, especially in the field of cardiovascular disease. In the scientific literature, there is sufficient evidence to support beyond any doubt the involvement of IL-8 in the establishment and preservation of the inflammatory micro-environment of the insulted vascular wall. However, how the information derived from in vitro studies and animal models can be applied in clinical practice has yet to be determined. In the present review, the available evidence regarding the role of IL-8 in cardiovascular disease is presented, and future perspectives are discussed.

KEYWORDS Chemokines; Interleukin 8; Cardiovascular disease; Biochemical markers

Time for primary review: 27 days


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.